Customers
MEGIN is proud to enter into a strategic partnership with FIND Neuro, a Mass General Hospital backed organization
MEGIN is delighted to announce a partnership with FIND Neuro, a disruptive start-up that reconstructs brain network maps to enable treatment of neurological diseases. FIND Neuro originated at Mass General Hospital and was co-founded by Dr. Noam Peled (CEO), Prof...
MEGIN announces sale and installation of TRIUX™ neo to Simon Fraser University
HELSINKI, FINLAND (October 5, 2023) - MEGIN is delighted to announce the sale and installation of our latest magnetoencephalography (MEG) technology, the TRIUX™ neo, to Simon Fraser University’s (SFU) core facility, ImageTech Lab. Located in British Columbia, SFU is...
Hiroshima University announces the sale of the first TRIUX™ neo in Japan
Hiroshima University Hospital press release – an announcement from our customer-partner Hiroshima University Hospital established its Epilepsy Center in January 2014. The Epilepsy Center has since been responsible for providing tertiary medical care as part of the...
Fixel Institute expands care with new neuroimaging and clinical research suites
A 15,000-square-foot neuroimaging suite that includes four high-tech imaging machines — including one of just three in the Southeast — opened Monday as the Norman Fixel Institute for Neurological Diseases at UF Health moves into a new phase of its growth.
MEGIN’s latest global customer survey finds customers are extremely satisfied with the customer service, project management and installation offered by MEGIN
Earlier this year, as part of its commitment to continually improving its customer service, MEGIN partnered with B2B international – a full-service market research company, to issue a global satisfaction survey to its customers, looking closely at the service MEGIN...
Bridging the gap: Adopting innovative technology in UK clinical settings
The role of Magnetoencephalography (MEG) technology, its clinical use in the UK, and a vision for the future.
Advanced Imaging in Epilepsy: How MEG Can Assist in Surgery
In this webinar, viewers will learn how MEG is a key part of the epilepsy surgery evaluation, including information about the basics and safety of a MEG study, and hear about how MEG can help the surgeon by mapping key functions (speech, motor, and vision) onto their MRI for use in the operating room.
MEGIN joins over 30 UK HealthTech pioneers on ABHI mission to bolster trade ties in California
MEGIN is delighted to be among the delegates of leading UK innovators heading to California this week (12-16 September 2022) as part of ABHI’s mission to bolster trade partnerships and promote the strengths of UK HealthTech stateside. The visit builds on the successes...
MEGIN joins over 20 UK HealthTech innovators on ABHI mission to strengthen trade partnerships in Tennessee
This month, MEGIN is delighted to be among the delegate of leading UK HealthTech innovators heading to Tennessee to strengthen trade links and showcase their products and services to the US market. The visit marks the second major US trade mission organised this year...
MEGIN joins 28 UK HealthTech pioneers on ABHI mission to strengthen trade relations in Texas
MEGIN is excited to be among the delegate of pioneering HealthTech companies heading to Texas as part of the first major US trade mission organized by the Association of British HealthTech Industries (ABHI) since the COVID-19 pandemic. The visit marks the launch of a...
MEGIN announces sale of TRIUX™ neo to University of Nebraska Medical Center
HELSINKI, FINLAND (March 07, 2022) - MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX™ neo, by the University of Nebraska Medical Center (UNMC). UNMC scientists and clinicians are at the leading...
Geneva at the heart of the human brain
It’s a first in Switzerland: the Human Neuroscience Platform (HNP) will host a magnetoencephalography (MEG) facility next summer with the purchase of a MEGIN TRIUX™ neo, a state-of-the-art scanner that allows non-invasive analysis of brain activity. This acquisition is the result of a partnership between several institutions located at the Campus Biotech and promises new breakthroughs in the understanding and treatment of brain disorders such as Alzheimer’s, epilepsy or aphasia.